172 related articles for article (PubMed ID: 38036941)
1. Vonoprazan and amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection: A systematic review and meta-analysis.
Du RC; Hu YX; Ouyang Y; Ling LX; Xu JY; Sa R; Liu XS; Hong JB; Zhu Y; Lu NH; Hu Y
Helicobacter; 2024; 29(1):e13039. PubMed ID: 38036941
[TBL] [Abstract][Full Text] [Related]
2. Vonoprazan-amoxicillin dual therapy for
Zhou BG; Mei YZ; Jiang X; Zheng AJ; Ding YB
Saudi J Gastroenterol; 2023; 29(6):347-357. PubMed ID: 37602635
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
Zhang WL; Lin BS; Li YY; Ding YM; Han ZX; Ji R
Digestion; 2023; 104(4):249-261. PubMed ID: 37015201
[TBL] [Abstract][Full Text] [Related]
4. Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy.
Qian HS; Li WJ; Dang YN; Li LR; Xu XB; Yuan L; Zhang WF; Yang Z; Gao X; Zhang M; Li X; Zhang GX
Am J Gastroenterol; 2023 Apr; 118(4):627-634. PubMed ID: 36729890
[TBL] [Abstract][Full Text] [Related]
5. Comparison of vonoprazan-based dual therapy with vonoprazan-based bismuth quadruple therapy for treatment-naive patients with Helicobacter pylori infection: A propensity score matching analysis.
Liu Z; Chen X; Sun DJ; Zhao WW; Kou L; Zheng WW; Hao JR; Gao FY
Medicine (Baltimore); 2024 Mar; 103(10):e37476. PubMed ID: 38457567
[TBL] [Abstract][Full Text] [Related]
6. Ten-Day Vonoprazan-Amoxicillin Dual Therapy vs Standard 14-Day Bismuth-Based Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Multicenter Randomized Clinical Trial.
Yan TL; Wang JH; He XJ; Zhu YB; Lu LJ; Wang YJ; Wang ZW; Gao JG; Xu CF; Ma H; Luan SM; Li L; Chen Y
Am J Gastroenterol; 2024 Apr; 119(4):655-661. PubMed ID: 37975609
[TBL] [Abstract][Full Text] [Related]
7. Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
Ouyang Y; Wang M; Xu YL; Zhu Y; Lu NH; Hu Y
J Gastroenterol Hepatol; 2022 Sep; 37(9):1666-1672. PubMed ID: 35716370
[TBL] [Abstract][Full Text] [Related]
8. Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: A multicenter randomized controlled trial in China.
Hu J; Mei H; Su NY; Sun WJ; Zhang DK; Fan LL; He P; Pan J; Wang XW; Zou PY; Liu YX; Guo Y; Lan CH
Helicobacter; 2023 Aug; 28(4):e12970. PubMed ID: 37160689
[TBL] [Abstract][Full Text] [Related]
9. Vonoprazan-based therapies versus PPI-based therapies in patients with H. pylori infection: Systematic review and meta-analyses of randomized controlled trials.
Liu L; Shi H; Shi Y; Wang A; Guo N; Li F; Nahata MC
Helicobacter; 2024; 29(3):e13094. PubMed ID: 38790090
[TBL] [Abstract][Full Text] [Related]
10. Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
Zhou BG; Jiang X; Ding YB; She Q; Li YY
Helicobacter; 2024; 29(1):e13040. PubMed ID: 37983865
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of vonoprazan-amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis.
Feng JH; Cheng J; Lao YJ; Huang K; Mou JL; Hu F; Lin ML; Lin J
Eur J Med Res; 2023 Aug; 28(1):272. PubMed ID: 37550781
[TBL] [Abstract][Full Text] [Related]
12. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line
Suzuki S; Gotoda T; Kusano C; Ikehara H; Ichijima R; Ohyauchi M; Ito H; Kawamura M; Ogata Y; Ohtaka M; Nakahara M; Kawabe K
Gut; 2020 Jun; 69(6):1019-1026. PubMed ID: 31915235
[TBL] [Abstract][Full Text] [Related]
13. Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study in China.
Gao W; Teng G; Wang C; Xu Y; Li Y; Cheng H
Helicobacter; 2022 Oct; 27(5):e12918. PubMed ID: 35877765
[TBL] [Abstract][Full Text] [Related]
14. Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study.
Han YY; Zhou L; Hu YL; Ding XW; Long H; Liu F; Xu M; Zhang ZY; Li SL; Wang QY; Su CX; Chen Y; Chen J; Lin Y; Li PY
J Gastroenterol; 2023 Dec; 58(12):1167-1177. PubMed ID: 37777987
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan.
Gotoda T; Kusano C; Suzuki S; Horii T; Ichijima R; Ikehara H
J Gastroenterol; 2020 Oct; 55(10):969-976. PubMed ID: 32666199
[TBL] [Abstract][Full Text] [Related]
16. Low-dose or high-dose amoxicillin in vonoprazan-based dual therapy for Helicobacter pylori eradication? A systematic review and meta-analysis.
Ju KP; Kong QZ; Li YY; Li YQ
Helicobacter; 2024; 29(1):e13054. PubMed ID: 38900537
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
Chen S; Shen W; Liu Y; Dong Q; Shi Y
Chin Med J (Engl); 2023 Jul; 136(14):1690-1698. PubMed ID: 37469024
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Vonoprazan-Amoxicillin Dual Regimen With Varying Dose and Duration for Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Study.
Peng X; Yao JY; Ma YQ; Li GH; Chen HW; Wan Y; Liang DS; Zhang M; Zhi M
Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1210-1216. PubMed ID: 38309492
[TBL] [Abstract][Full Text] [Related]
19. Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy: a multicenter, prospective, randomized, parallel-controlled study.
Peng X; Chen HW; Wan Y; Su PZ; Yu J; Liu JJ; Lu Y; Zhang M; Yao JY; Zhi M
Clin Exp Med; 2023 Nov; 23(7):4011-4019. PubMed ID: 37115412
[TBL] [Abstract][Full Text] [Related]
20. Research trends on vonoprazan-based therapy for Helicobacter pylori eradication: A bibliometric analysis from 2015 to 2023.
Du RC; Ouyang YB; Lu NH; Hu Y
Helicobacter; 2023 Oct; 28(5):e13012. PubMed ID: 37515414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]